Conclusion TME technology is easy to master, with clear anatomical level and low incidence of local tumor recurrence.
结论TME技术易于掌握，解剖层次清晰，肿瘤局部复发率低，值得临床推广应用。
The patients had were followed up for 3 to 57 months (mean 26 months) with no surgical complication or local tumor recurrence.
术后平均随访26（3~57）个月，未见并发症及肿瘤局部复发及转移。
Postoperatively, there was local tumor recurrence or distal metastasis in 6.9% of patients with incidental RCC and 30.2% of symptomatic patients.
术后局部复发或远处转移情形，偶发性肾肿瘤比有症状的肾肿瘤低（6.9%比30.2%）。
Because the local recurrence following BCS is the most chief obstacle, the qualification of locally control is to excise enough breast tissue around the tumor.
局部复发是影响“保乳”成功与否的最大障碍，因此，切除足够的组织量是实现局部控制安全性的主要条件。
Tumor size, histopathological type, number of positive axillary lymph nodes are the main factors influencing local recurrence.
原发肿瘤大小、病理组织学类型、腋淋巴结阳性数是影响局部复发的主要因素。
This change may play an important role clinically in reducing postoperative local recurrence and metastasis, and strengthening the therapeutic effects of thermal ablation on tumor.
这对于减少肿瘤的局部复发和远处转移，增加热凝固治疗抗肿瘤疗效具有重要的临床意义。
Younger age and female gender had a propensity for local recurrence, suggesting that the biological behavior of desmoid tumor may depend on the status of the disease at presentation.
较年青者和女性有复发倾向，表明韧带样瘤的生物学行为主要依靠疾病特征表现。
Objective: To prevent local recurrence of giant cell tumor of bone (GCT).
目的：防止骨巨细胞瘤的局部复发。
It can kill or inhibit tumor cells, reduce or delay the chance of local recurrence or metastasis, and improve prognosis with a broad prospect.
杀死或抑制肿瘤病灶，减少、迟局部复发或转移，改善预后，有着广阔发展前景。
Background: Giant cell tumor of bone (GCT) is frequently seen in bone tumors, with local aggression and high risk of recurrence.
背景：骨巨细胞瘤是一种常见的骨肿瘤，其有较强的局部侵蚀性，术后复发率较高。
We had 20 patients receiving adjuvant chemotherapy and 62 patients of local-advanced or with tumor recurrence or metastasis receiving palliative chemotherapy.
其中行术后辅助化疗20例，因局部晚期或复发、转移行姑息化疗62例。
We had 20 patients receiving adjuvant chemotherapy and 62 patients of local-advanced or with tumor recurrence or metastasis receiving palliative chemotherapy.
其中行术后辅助化疗20例，因局部晚期或复发、转移行姑息化疗62例。
应用推荐